
Please try another search
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. The company offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. It also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Detlef Bockenhauer | - | 2019 | Member of Scientific Advisory Board |
Thibaut Roulon | 48 | 2011 | Director |
Gema Ariceta | - | - | Member of Scientific Advisory Board |
André Ulmann | 75 | 2020 | Chief Medical Officer & Non-Voting Director |
Larry Greenbaum | - | - | Member of Scientific Advisory Board |
Charlotte E. Sibley | 78 | 2018 | Independent Director |
Elena Levtchenko | - | - | Member of Scientific Advisory Board |
Bertrand Knebelmann | - | - | Member of Scientific Advisory Board |
Philippe Boucheron | 58 | 2011 | Chairman of the Board |
Didier Laurens | 58 | 2021 | CEO, MD, General Director & Director |
Catherine Dunand | 64 | 2017 | Director |
Laurent Cassedanne | 57 | 2021 | Deputy CEO, Deputy GM & Head Pharmacist and Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review